Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Amanda L. Facklam
Observed names:
Amanda Facklam,
Facklam, Amanda L.
Institutions:
Koch Institute for Integrative Cancer Research At MIT,
Massachusetts Institute of Technology
Observed institutions:
Johns Hopkins University,
Koch Institute for Integrative Cancer Research At MIT,
Massachusetts Institute of Technology
ORCID:
0000-0002-4519-4158
Observed ORCID:
0000-0002-4519-4158
OpenAlex ID:
A5045668164
A retrievable implant for the long-term encapsulation and survival of therapeutic xenogeneic cells
2020
·
Suman Bose
, Lisa R. Volpatti
, et al.
·
Nature Biomedical Engineering
·
186
Biomaterials for Personalized Cell Therapy
2019
·
Amanda L. Facklam
, Lisa R. Volpatti
, et al.
·
Advanced Materials
·
158
Microgel encapsulated nanoparticles for glucose-responsive insulin delivery
2020
·
Lisa R. Volpatti
, Amanda L. Facklam
, et al.
·
Biomaterials
·
68
A wireless, battery-free device enables oxygen generation and immune protection of therapeutic xenotransplants in vivo
2023
·
Siddharth R. Krishnan
, Claudia Liu
, et al.
·
Proceedings of the National Academy of Sciences
·
44
Partially Oxidized Alginate as a Biodegradable Carrier for Glucose‐Responsive Insulin Delivery and Islet Cell Replacement Therapy
2022
·
Lisa R. Volpatti
, Matthew A. Bochenek
, et al.
·
Advanced Healthcare Materials
·
28
Micropattern size‐dependent endothelial differentiation from a human induced pluripotent stem cell line
2015
·
Sravanti Kusuma
, Quinton Smith
, et al.
·
Journal of Tissue Engineering and Regenerative Medicine
·
27
Characterizing Human Pluripotent-Stem-Cell-Derived Vascular Cells for Tissue Engineering Applications
2014
·
Sravanti Kusuma
, Amanda Facklam
, et al.
·
Stem Cells and Development
·
26
Enhancing the Functionality of Immunoisolated Human SC‐βeta Cell Clusters through Prior Resizing
2024
·
Matthew A. Bochenek
, Ben Walters
, et al.
·
Small
·
10
PDF
Abstract 742: PYX-201, a stroma-targeting ADC composed of an anti-EDB+FN antibody conjugated to Auristatin0101, demonstrates strong anti-tumor efficacy across multiple human cancer indications in pre-clinical PDX tumor models
2024
·
Nicolas Severe
, Amanda Facklam
, et al.
·
Cancer Research
·
4
Crystallized colony-stimulating factor-1 receptor inhibitor protects immunoisolated allo but not xeno transplants in primates
2026
·
Matthew A. Bochenek
, Shady Farah
, et al.
·
Science Translational Medicine
·
1
Abstract 3120: Evaluation of PYX-201, an EDB+FN-targeting ADC, in a comprehensive PDX mini-trial study enables identification of gene signatures associated with anti-tumor activity
2025
·
Amanda Facklam
, Justin Trickett
, et al.
·
Cancer Research
·
1
Abstract 3137: The combination of anti-PD1 and a mouse analog of PYX-201, an antibody-drug conjugate targeting the extra-domain B splice variant of fibronectin (EDB+FN), shows greater anti-tumor efficacy than either treatment alone
2025
·
Anthony Burt Rodriguez
, Amanda Facklam
, et al.
·
Cancer Research
·
1
Abstract 4406: Mouse analog of micvotabart pelidotin, an antibody-drug conjugate targeting extradomain-B of fibronectin, demonstrates anti-tumor efficacy in an immunotherapy-refractory syngeneic head and neck squamous cell carcinoma model
2026
·
Anthony B. Rodriguez
, Amanda Facklam
, et al.
·
Cancer Research
Abstract A112: Micvotabart pelidotin induces immunogenic cell death markers and activates tumor immune cells in pre-clinical studies
2025
·
Matthew Iovino
, Anthony B. Rodriguez
, et al.
·
Molecular Cancer Therapeutics
Abstract A115: Mouse analog of micvotabart pelidotin sensitizes a refractory syngeneic breast cancer model to anti-PD1 therapy
2025
·
Anthony B. Rodriguez
, Amanda Facklam
, et al.
·
Molecular Cancer Therapeutics
Abstract A116: Characterization of micvotabart pelidotin target binding properties and extracellular payload release
2025
·
Chuan Shen
, Matthew Iovino
, et al.
·
Molecular Cancer Therapeutics
Show more works
View as search
Works count:
17
Citation count:
556
H-index:
8
I10-index:
8
Year
Topic
Type